Targeting Rare Diseases
AOP Orphan is a European pioneer in the development, production and marketing of treatments for people with rare and special diseases.
“Introducing treatments to the Nordic market is a complex task we are eager to master for the benefit of patients!”
Facts & Figures
AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Swedish health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Sweden occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 2017 and this is where AOP Orphan started its activities in the Nordics region. AOP Orphan Sweden is comprised of experienced and qualified team members in the Marketing & Sales, and Medical for all three therapeutic divisions.
Vision & Mission
Milestones
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Orphan.
Foundation of AOP Orphan in Vienna
The Orphan Regulation EC no 141/2000
1st Approval of Anagrelide in Europe
European Union Expansion
Prostacyclin Analogues Approval
JAK2 Discovery
Renaissance of Interferon (IFNα)
UDCA Designation
Tetrabenazine Approval in Central Europe
Nabilone Approval in Austria
Start of the PROUD PV Study
Beta-blocker for severe sepsis
Pitolisant approval
Landiolol approval
Treprostinil and PAH
BESREMi® Approval
Corporate culture
Thanks to many years of experience in the provision of complex and individualized treatments, AOP Orphan gained special expertise and market presence in the field of rare diseases.
Since its very start AOP Orphan has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Orphan conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Orphan corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Orphan is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
From its inception AOP Orphan's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.
The future
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Orphan’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.